Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVADER AAV8
- Development stage
- Preclinical
- Lead developer
- Chameleon Biosciences
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
- Administration
- Intravenous
01
Overview
EVADER AAV8 is a next-generation gene therapy vector developed by Chameleon Biosciences. It utilizes the EVADER (Enveloped Virus After De-Enveloping Re-Enveloping) platform, which consists of adeno-associated virus (AAV) particles, specifically serotype 8, enclosed within a lipid bilayer membrane. This membrane is engineered with checkpoint immunosuppressive molecules to shield the vector from the host's anti-AAV immune response, including neutralizing antibodies and T-cell activation. The lead candidate using this vector carries a human Factor IX (FIX) transgene for the treatment of severe hemophilia B. By evading the immune system, the platform aims to allow for lower dosing and the potential for repeat administration, which is a significant limitation of traditional AAV-based gene therapies.
- Other names
- AAV8 EVADER/FIXEVADER platform
02
Targets
DNANeuraminidasePre-existing anti-adeno-associated virus 8 neutralizing antibodiesPDCD1 (Programmed cell death protein 1 receptor)F9 (Coagulation Factor IX)
Beyond the preview
Go deeper on EVADER AAV8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVADER AAV8.